Cambrex Corp. To Acquire Halo Pharma For $425 Mln - Quick Facts

(RTTNews) - Cambrex Corp. (CBM) announced a definitive agreement to acquire Halo Pharma (Halo), a dosage form Contract Development and Manufacturing Organization, majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million.

Halo operates two state-of-the-art, GMP compliant facilities located in Whippany, NJ, USA and Montreal, Québec, Canada. Halo is currently engaged in more than 100 product development projects for over 70 customers, and is expected to generate over $100 million in annual revenue in 2018. Halo's 450-person workforce will join Cambrex's 1,200 employees across the U.S. and Europe.